Alcohol use disorder is a serious health problem around the world. It affects millions of people and is linked to about 5 percent of all deaths each year.
People who struggle with alcohol use may find it hard to control how much they drink, even when it causes harm to their health, relationships, and daily life. Although there are some treatments available, many people do not respond well to them, which means there is a strong need for new and better options.
A new study has explored an unexpected possibility. Researchers tested whether a medicine commonly used for weight loss and diabetes, called semaglutide, could help reduce heavy drinking. This drug belongs to a group known as GLP-1 receptor agonists.
These medicines work by affecting appetite and the way the body processes food. Recently, scientists have started to wonder if they might also influence behaviors such as alcohol use.
The study was carried out in Denmark at a mental health center. It included 108 adults who had both obesity and alcohol use disorder and were actively seeking treatment.
All participants received cognitive behavioral therapy, which is a common type of talk therapy that helps people understand and change their habits. At the same time, they were randomly assigned to receive either a weekly semaglutide injection or a placebo, which is a treatment with no active drug.
At the beginning of the study, participants reported heavy drinking on about 17 days out of the past 30 days. Heavy drinking usually means consuming a large amount of alcohol in a short time, which increases the risk of harm. Over the next six months, both groups showed improvement, but the group receiving semaglutide improved more.
After six months, people who received semaglutide reported only about five heavy drinking days in the past month. In comparison, those in the placebo group still had around nine heavy drinking days.
This means the reduction in heavy drinking was about 12 days for the semaglutide group, compared to eight days for the placebo group. This difference suggests that the drug may have helped people reduce their alcohol intake more effectively.
The study also measured the total amount of alcohol consumed. At the start, participants drank about 2,200 grams of alcohol over 30 days. After treatment, those taking semaglutide reduced this to around 650 grams, while the placebo group reduced it to about 1,175 grams. This shows a clear difference between the two groups.
The findings were published in the journal The Lancet, which is a highly respected medical journal. This gives the study strong credibility. However, the researchers also pointed out some limitations. The study was relatively small, and there was no follow-up after the trial ended. This means we do not know if the benefits lasted over time.
Reviewing these results, the study offers an interesting and hopeful direction for future research. It suggests that semaglutide may affect not only appetite for food but also cravings for alcohol. This could open a new way of treating alcohol use disorder, especially for people who also struggle with obesity.
However, more research is needed before this treatment can be widely used. Larger studies and longer follow-up periods will help confirm whether the results are consistent and long-lasting. It is also important to understand how the drug works in the brain to influence drinking behavior.
In conclusion, this study provides early evidence that semaglutide may help reduce heavy drinking. While it is not yet a standard treatment for alcohol use disorder, it shows strong potential. If future studies confirm these findings, this medicine could become an important tool in helping people reduce alcohol use and improve their health.
If you care about alcoholism, please read studies that your age may decide whether alcohol is good or bad for you, and people over 40 need to prevent dangerous alcohol/drug interactions.
For more information about alcohol, please see recent studies about moderate alcohol drinking linked to high blood pressure, and results showing this drug combo shows promise for treating alcoholism.
Source: The Lancet.
